Erratum: The effect of hyperbaric oxygen therapy on bladder symptoms of female patients with overactive bladder (Undersea Hyperb Med (2022) 49: 3 (383-390) DOI: 10.22462/05.06.2022.13)

The abstract in the above-named paper, which appeared on page 383 of the 49(3) issue, contained an error. It read: “The mean changes in the ICIQ-SF, OAB-V8, and IIQ-7 scores in the third month of treatment in Group 1 were 4.12 ±...” This first number should be “-4.12” - i.e., a negative value. The corrected abstract reads: Hamarat MB, Arslan A. The effect of hyperbaric oxygen therapy on bladder symptoms of female patients with overactive bladder. Undersea Hyperb Med. 2022 Third Quarter; 49(3):383-390. Overactive bladder (OAB) is a disease with symptoms such as feelings of urgency, nocturia, and frequent urination which is usually accompanied by urinary incontinence. We aimed to assess the effect of hyperbaric oxygen (HBO₂) therapy on the symptoms of female patients with overactive bladder. This study is a prospective observational cohort study. The patients were analyzed into two groups. The patients who received HBO₂ therapy were in Group 1, and the patients who received mirabegron treatment were in Group 2. The symptom scores and quality of life scores of the patients before and after treatment were recorded and compared. Significant improvement in symptom scores were seen in both groups after treatment compared to baseline. The study included 31 patients in Group 1 and 44 patients in Group 2. The mean changes in the ICIQ-SF, OAB-V8, and IIQ-7 scores in the third month of treatment in Group 1 were -4.12 ± 3.51, -10.70 ± 6.92, and -4.51 ± 2.68, respectively. The corresponding mean score changes in Group 2 were -4.31 ± 3.16, -11.22 ± 5.93, and -3.68 ± 2.67, respectively. The mean changes in all three scores were not significantly different between Groups 1 and 2 (p = 0.81, 0.73, and 0.19, respectively). We observed that HBO₂ treatment improved quality of life by reducing the symptom score in patients with OAB. Moreover, this effect continued in the third month after the treatment. Considering the efficacy and side effect profiles of the available treatments, HBO₂ therapy may be a new treatment alternative in OAB.